How I treat refractory and early relapsed acute myeloid leukemia

Slides:

Advertisements

Similar presentations

台北榮總血液腫瘤科楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.

Advertisements

Jennifer Vaughn, MD Bart Scott, MD.  Myelodysplastic syndromes ◦ Clonal hematopoetic disorder in which ineffective or dysplastic cell production leads.

LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

1 Stone RM et al. Proc ASH 2015;Abstract 6.

REVIEW AML RECURRENCE R3 조경민.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.

Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia by Sebastian.

Gupta V, Tallman MS, Weisdorf DJ

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation by Jan Moritz Middeke,

Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Has MRD monitoring superseded other prognostic factors in adult ALL?

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT) Masumi.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML by Renato Bassan, Tamara Intermesoli, Arianna.

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.

Timing for HCT Consultation

by Lucy A. Godley, and Akiko Shimamura

by Jan J. Cornelissen, and Didier Blaise

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:

How I treat T-cell acute lymphoblastic leukemia in adults

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.

Presentation transcript:

How I treat refractory and early relapsed acute myeloid leukemia by Felicitas Thol, Richard F. Schlenk, Michael Heuser, and Arnold Ganser Blood Volume 126(3):319-327 July 16, 2015 ©2015 by American Society of Hematology

Algorithm for patients with early relapsed/refractory AML Algorithm for patients with early relapsed/refractory AML. When diagnosing primary refractory AML/early relapse patients need to be evaluated for allogeneic HSCT and/or a suitable trial. Algorithm for patients with early relapsed/refractory AML. When diagnosing primary refractory AML/early relapse patients need to be evaluated for allogeneic HSCT and/or a suitable trial. DLI, donor lymphocyte infusion; HCT-CI, Hematopoietic Cell Transplant–Comorbidity Index; LDAC, low-dose cytarabine; MEC, mitoxantrone, etoposide, cytarabine. #, § indicate that clinical trials should consider the patient’s performance status; that is, fit patients should receive more intense study medications (in most cases including chemotherapy) compared with unfit patients. Felicitas Thol et al. Blood 2015;126:319-327 ©2015 by American Society of Hematology

The candidate targets in AML The candidate targets in AML. cKIT, c-kit receptor tyrosine kinase; IDH, isocitrate dehydrogenase; ras, rat sarcoma. The candidate targets in AML. cKIT, c-kit receptor tyrosine kinase; IDH, isocitrate dehydrogenase; ras, rat sarcoma. Felicitas Thol et al. Blood 2015;126:319-327 ©2015 by American Society of Hematology